Skip to content
2000
Volume 18, Issue 8
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

Asthma is an inflammatory disease which affects millions of people worldwide. Therefore, it is necessary to search for new sources of therapies for the treatment of these patients in order to improve their quality of life. From content analysis of literature of new therapeutic targets, there are various targets and drugs reported to be promising for the treatment of asthma. Interleukins involved in inflammatory processes are often presented as candidate targets for new drugs. The action of such therapeutics would not only affect interleukins, but also their receptors. Small molecules (e.g. ligustrazine and SP600125) and large molecule antibodies (e.g. lebrikizumab, benralizumab, dupilumab) are being considered as novel agents for the pharmacotherapy of asthma. Therefore, through this research, we can see advances in the search for new targets and promising drugs to treat asthma. It is expected that these new drug candidates will eventually be approved and marketed so that asthma patients can use them to enhance their quality of life.

Loading

Article metrics loading...

/content/journals/mrmc/10.2174/1389557517666170927145011
2018-05-01
2025-10-10
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/1389557517666170927145011
Loading

  • Article Type:
    Review Article
Keyword(s): Asthma; drugs; monoclonal antibody; natural products; targets; therapeutic targets
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test